Primary results of the brazilian registry of atherothrombotic disease (NEAT)

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PORTFOLIO
Autores
SILVA, Pedro G. M.
NASCIMENTO, Charlene Troiani do
PEDROSA, Rodrigo Pinto
NAKAZONE, Marcelo Arruda
NASCIMENTO, Michel Ulloffo do
MELO, Leiliandry de Araujo
JUNIOR, Osvaldo Lourenco Silva
ZIMMERMANN, Sergio Luiz
MELO, Rodrigo Morel Vieira de
BERGO, Ricardo Reinaldo
Citação
SCIENTIFIC REPORTS, v.14, n.1, article ID 4222, 10p, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
There is limited contemporary prospective real-world evidence of patients with chronic arterial disease in Latin America. The Network to control atherothrombosis (NEAT) registry is a national prospective observational study of patients with known coronary (CAD) and/or peripheral arterial disease (PAD) in Brazil. A total of 2,005 patients were enrolled among 25 sites from September 2020 to March 2022. Patient characteristics, medications and laboratorial data were collected. Primary objective was to assess the proportion of patients who, at the initial visit, were in accordance with good medical practices (domains) for reducing cardiovascular risk in atherothrombotic disease. From the total of patients enrolled, 2 were excluded since they did not meet eligibility criteria. Among the 2,003 subjects included in the analysis, 55.6% had isolated CAD, 28.7% exclusive PAD and 15.7% had both diagnoses. Overall mean age was 66.3 (+/- 10.5) years and 65.7% were male patients. Regarding evidence-based therapies (EBTs), 4% were not using any antithrombotic drug and only 1.5% were using vascular dose of rivaroxaban (2.5 mg bid). Only 0.3% of the patients satisfied all the domains of secondary prevention, including prescription of EBTs and targets of body-mass index, blood pressure, LDL-cholesterol, and adherence of lifestyle recommendations. The main barrier for prescription of EBTs was medical judgement. Our findings highlight that the contemporary practice does not reflect a comprehensive approach for secondary prevention and had very low incorporation of new therapies in Brazil. Large-scale populational interventions addressing these gaps are warranted to improve the use of evidence-based therapies and reduce the burden of atherothrombotic disease.ClinicalTrials.gov NCT04677725
Palavras-chave
Cardiovascular diseases, Guideline adherence, Registries
URI
https://observatorio.fm.usp.br/handle/OPI/59286
Referências
  1. Berwanger O, 2013, ARQ BRAS CARDIOL, V100, P212, DOI 10.5935/abc.20130062
  2. Bhatt DL, 2006, JAMA-J AM MED ASSOC, V295, P180, DOI 10.1001/jama.295.2.180
  3. Bonaca MP, 2020, NEW ENGL J MED, V382, P1994, DOI 10.1056/NEJMoa2000052
  4. Cantú-Brito C, 2012, CLIN CARDIOL, V35, P451, DOI 10.1002/clc.22005
  5. Collet JP, 2021, EUR HEART J, V42, P1289, DOI 10.1093/eurheartj/ehaa575
  6. Eikelboom JW., 2017, NEW ENGL J MED, V377, P1319, DOI [DOI 10.1056/NEJMOA1709118, 10.1056/NEJMoa1709118]
  7. Gerhard-Herman MD, 2017, CIRCULATION, V135, pE686, DOI 10.1161/CIR.0000000000000470
  8. Golledge J, 2022, NAT REV CARDIOL, V19, P456, DOI 10.1038/s41569-021-00663-9
  9. Knuuti J, 2020, EUR HEART J, V41, P407, DOI 10.1093/eurheartj/ehz425
  10. Komajda M, 2016, EUR HEART J, V37, P152, DOI 10.1093/eurheartj/ehv437
  11. Libby P, 1998, Vasc Med, V3, P225, DOI 10.1177/1358836X9800300309
  12. Lloyd-Jones DM, 2010, CIRCULATION, V121, P586, DOI 10.1161/CIRCULATIONAHA.109.192703
  13. Machline-Carrion MJ, 2019, JAMA CARDIOL, V4, P408, DOI 10.1001/jamacardio.2019.0649
  14. Silva PGMDE, 2021, ARQ BRAS CARDIOL, V116, P108, DOI 10.36660/abc.20190885
  15. Silva PGMDE, 2018, INT J CARDIOL, V267, P13, DOI 10.1016/j.ijcard.2018.05.102
  16. Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2
  17. Nguyen ATH, 2021, AM J CARDIOL, V138, P20, DOI 10.1016/j.amjcard.2020.10.019
  18. Ohman EM, 2006, AM HEART J, V151, DOI 10.1016/j.ahj.2005.11.004
  19. Olesen KKW, 2021, BMJ OPEN DIAB RES CA, V9, DOI 10.1136/bmjdrc-2020-001803
  20. Thompson S.K., 2012, Sampling, VThird, DOI 10.1002/9781118162934
  21. Visseren Frank L J, 2021, Eur Heart J, V42, P3227, DOI 10.1093/eurheartj/ehab484
  22. Yusuf S, 2020, LANCET, V395, P795, DOI 10.1016/S0140-6736(19)32008-2

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor